The chromatography resin market is estimated to grow to USD 3.8 billion by 2027 from USD 2.6 billion in 2022, at a CAGR of 8.0%. Growing pharmaceuticals & biopharmaceutical R&D activities is expected to support the growth of the chromatography resin market. However, lack of adequate skilled professionals is restraining the growth of the market. On the other hand, increasing demand for disposable pre-packed columns has created opportunities for manufacturers.

Bio-Rad Laboratories Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Tosoh Corporation (Japan), Bio-Works Technologies AB (Sweden), Avantor Performance Materials, Inc. (US), Mitsubishi Chemical Corporation (Japan), among others are the major players in this market.

To know about the assumptions considered for the study download the pdf brochure

Bio-Rad Laboratories, Inc. is a multinational manufacturer and worldwide distributor of life science research and clinical diagnostics products. Bio-Rad operates their business through three reportable segments, namely, life science, clinical diagnostics, and others. Both clinical diagnostics and life science operate worldwide. The company offers chromatography resins through the life science segment. The company has direct distribution channels in over 35 countries outside the US through subsidiaries whose focus is sales, customer service and product distribution. Sales efforts are supplemented by distributors and agents in some locations outside and inside these 35 countries such as North America, South America, Latin America, Europe, and Asia Pacific.

• In April 2020, Bio-Rad Laboratories, Inc. announced the acquisition of Celsee, Inc., a company that offers instruments and consumables for the isolation, detection, and analysis of single cells. Celsees innovative products and technologies are expected to extend Bio-Rads reach into the rapidly growing world of precision medicine and single-cell analysis as both offer enhanced insight into disease, diagnosis, and treatment.

The Danaher Corporation is an US-based globally diversified conglomerate, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. Danaher Corporation operates their business through three reportable segments, namely, life sciences, diagnostics, and environmental & applied solutions. Danaher is offering chromatography resins through its acquired standalone company named, Cytiva. The company operate in 40 countries and territories covering Europe, Asia, North and Latin America, and the Middle East.

• In April 2021, Solis BioDyne, as a manufacturer of molecular biology applications, including reagents to analyze DNA from humans and therefore part of COVID-19 testing, Solis BioDyne turned to Danaher to support production ramp-up. Solis BioDyne practiced and learned how to manufacture greater quantities with a more efficient process at Testa Center in Uppsala, Sweden and helped Danaher expand its business in affinity chromatography resin product.
• In March 2020, Danaher Corporation completed the acquisition of the Biopharma business from General Electric Companys life sciences division. As part of Danaher, the business is called Cytiva and will be a standalone operating company within Danahers life sciences segment.
• In December 2020, Danaher opened its new 80,000 square feet manufacturing facility in Shrewsbury, Massachusetts. The site has also benefited from the support of a Technology Investment Agreement entered in October 2019 with the Biomedical Advanced Research and Development Authority (BARDA). Xcellerex XDR bioreactors will be made at the new facility. This bioreactor will provide the flexible and scalable solutions for companies to manufacture biopharmaceuticals, vaccines, and antibodies.

Read More: https://www.marketsandmarkets.com/PressReleases/chromatography-resins.asp